Águeda Martínez‐Barriocanal

Universitat Autònoma de Barcelona — Spain

Medicine · Health Sciences

15h-index672citations47works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(6), Immune Cell Function and Interaction(6), Cancer Genomics and Diagnostics(6), Genetic factors in colorectal cancer(6), DNA Repair Mechanisms(5)

Publications47 total

RhoA downregulation in the murine intestinal epithelium results in chronic Wnt activation and increased tumorigenesis
iScience·2024· 5 citedOpen Access
Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors
Advanced Science·2023· 20 citedOpen Access
Supplementary Figure 4 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 3 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Data from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 5 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 5 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 6 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 7 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 8 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 7 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Data from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 2 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Text from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 4 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 1 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 3 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 6 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 2 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Text from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Diego Arango(33), Rocío Nieto(29), Helena Montanuy(21), José Antonio Casado(21), Llorenç Rovirosa(21), Marı́a José Ramı́rez(21), Carlos Carrascoso-Rubio(21), Pau Riera(21), Alan González(21), Enrique Lerma(21), Adriana Lasa(21), Jordi Carreras‐Puigvert(21), Thomas Helleday(21), Juan A. Bueren(21), Jordi Minguillón(21), Jordi Surrallés(21), Simó Schwartz(12), Joan Sayós(9), Higinio Dopeso(7), Estefanía Anguita(7)